Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.44 |
| ▸ | IKBKB | O14920 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.41 |
| ▸ | KCNN4 | O15554 | 5/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.38 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.37 |
| ▸ | CFTR | P13569 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL163352 | 0.89 | KCNMA1 (0.45) | GRIK1IKBKBMEN1JAK2EIF2AK2 | |
| SCHEMBL166771 | 0.86 | MAPK10 (0.45) | IKBKBMEN1KMT2AMAPK10KDM4E | |
| SCHEMBL159515 | 0.86 | AGTR1 (0.50) | MEN1KMT2ANTRK1KCNN4MAPK10 | |
| SCHEMBL165687 | 0.85 | KDM4E (0.53) | MEN1KMT2ACFTRALDH1A1KDM4E | |
| SCHEMBL28180282 | 0.79 | HDAC1 (0.62) | MEN1KMT2AHDAC1AGTR1NPC1 | |
| SCHEMBL165620 | 0.76 | MAPK14 (0.51) | IKBKBMEN1JAK2EIF2AK2KMT2A | |
| SCHEMBL163856 | 0.75 | MAPK8 (0.45) | IKBKBMEN1KMT2AKCNN4MAPK10 | |
| SCHEMBL160679 | 0.75 | KCNN4 (0.40) | IKBKBMEN1JAK2EIF2AK2KMT2A | |
| SCHEMBL166147 | 0.75 | MAPK8 (0.60) | MAPK10NPC1RAB9ASMN1; SMN2MAPK8 | |
| SCHEMBL163466 | 0.75 | JAK2 (0.54) | IKBKBMEN1JAK2EIF2AK2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9308207-B2 | JAK kinase modulating compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20150150874-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. (US) | 2015-06-04 | — | — | US | disclosed |
| US-8927711-B2 | JAK kinase modulating compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2015-01-06 | — | — | US | disclosed |
| EP-2401267-B1 | JAK KINASE MODULATING QUINAZOLINE DERIVATIVES AND THEIR USE IN METHODS | AMBIT BIOSCIENCES CORP (US) | 2014-01-15 | — | — | EP | disclosed |
| US-20130317045-A1 | THIENOPYRIDINE AND THIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-28 | — | — | US | disclosed |
| US-20130245014-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. (US) | 2013-09-19 | — | — | US | disclosed |
| EP-2611812-A1 | THIENOPYRIDINE AND THIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2611502-A1 | ADENOSINE A3 RECEPTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| US-8349851-B2 | JAK kinase modulating compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| WO-2012030918-A1 | ADENOSINE A3 RECEPTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030894-A1 | THIENOPYRIDINE AND THIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20120053176-A1 | ADENOSINE A3 RECEPTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. (US) | 2012-03-01 | — | — | US | disclosed |
| EP-2401267-A1 | JAK KINASE MODULATING QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20100317659-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. | 2010-12-16 | — | — | US | disclosed |
| WO-2010099379-A1 | JAK KINASE MODULATING QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150874-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | JAK2, JAK3, JAK1 | GRIK1 478/4885IKBKB 315/4885MEN1 3143/4885 |
| US-20130245014-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | JAK2, JAK3, JAK1 | GRIK1 478/4885IKBKB 315/4885MEN1 3143/4885 |
| US-20130317045-A1 | THIENOPYRIDINE AND THIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK2, JAK3, TYK2 | GRIK1 1188/4885IKBKB 668/4885MEN1 3037/4885 |
| US-20100317659-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | JAK2, JAK3, JAK1 | GRIK1 478/4885IKBKB 315/4885MEN1 3143/4885 |
| US-20120053176-A1 | ADENOSINE A3 RECEPTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | ADORA2A, ADORA3, ADORA1 | GRIK1 629/4885IKBKB 1224/4885MEN1 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.